Chronic kidney disease (CKD) is a condition where the kidneys gradually lose function over time, leading to kidney failure. Currently, there is no cure for CKD, and the treatment options available are limited. However, recent studies have shown that mesenchymal stem cells (MSCs) may be a promising treatment option for CKD.
MSCs are cells that have the ability to differentiate into various cell types and have immunomodulatory and anti-inflammatory properties. These properties make them a potential treatment option for CKD, as they may be able to reduce inflammation and improve kidney function.
Studies on MSCs therapy for CKD have shown promising results in preclinical models, including slowing the progression of the disease and reducing kidney fibrosis. In a clinical trial, two doses of allogeneic BMMSCs were given to 30 patients with diabetic nephropathy (DN), and the results showed no acute adverse events and a more stable or improved estimated glomerular filtration rate (eGFR) at week 12.
However, there are still challenges to MSCs therapy, including low cell survival after transplantation, mechanical stress during implantation, extracellular matrix loss during delivery, nutrition and oxygen deprivation at the recipient site, increasing age, and pathological circumstances. Novel approaches are required to improve the therapeutic efficacy of MSCs in pathophysiological conditions.
In conclusion, while MSCs therapy for CKD shows promise, more research is needed to validate its efficacy and safety. Nonetheless, it remains an exciting and emerging area of research for the treatment of CKD.
This is a summary of the article: Stem Cells: A new therapeutic tool for chronic kidney disease